



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/21 (03-03)  
Approved for use through 4/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/617,038
		Filing Date	July 11, 2003
		First Named Inventor	Peter Andersen et al
		Group Art Unit	1614
		Examiner Name	
Total Number of Pages in this Submission	6	Attorney Docket Number	SSI5AUSA

**ENCLOSURES (check all that apply)**


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1 pg. Transmittal of Certified Copy with 14 pg. Foreign application 5-References Remarks
---	--	---

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual Name	HOWSON AND HOWSON Cathy A. Kodroff
Signature	
Date	January 5, 2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this date: 1-5-04

Typed or printed name	Lynn Brown-Fischer		
Signature		Date	January 5, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

*If you need assistance in completing the form, call 1 -800-PTO-9199 (1-800-786-9199) and select option 2.*

CUSTOMER NO. 00270



CUSTOMER NO. 00270

SSISUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of ) Group Art Unit: 1614  
Andersen et al )  
Appln. No. 10/617,038 ) Examiner:  
Filed: July 11, 2003 ) Confirmation No. 5215  
For: THERAPEUTIC TB VACCINE ) January 5, 2004

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B are attached and a copy of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Certificate of Mailing under 37 CFR 1.8  
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450  
On January 5, 2004.

Signature Lynn Brown-Fischer

Typed or printed Lynn Brown-Fischer

Item (S), US Patent No. 6,641,814, corresponds to application No. 09/050,739, cited in the background of the application. A copy of the claims from this application are enclosed.

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicant

By   
Cathy A. Kodroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Phone: (215) 540-9200  
Fax: (215) 540-5818



CUSTOMER NO. 00270

SSISUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of  
Peter Andersen et al

) Group Art Unit: 1614

)

) Examiner:

)

) Confirmation No. 5215

)

)

) January 5, 2004

Appln. No. 10/617,038

Filed: July 11, 2003

For: THERAPEUTIC TB VACCINE

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF CERTIFIED COPY

Sirs:

Attached please find the certified copy of the foreign application from which priority is claimed in the above-identified U.S. Patent application:

Country: Denmark  
Application No. PA 2000 00666  
Filing Date: April 19, 2000

Certificate of Mailing under 37 CFR 1.8  
I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service with sufficient postage  
As first class mail in an envelope addressed  
to: Commissioner for Patents, PO Box 1450,  
Alexandria, VA 22313-1450 on  
January 5, 2004.

Signature Lynn Brown-Fischer

Printed Lynn Brown-Fischer

Repectfully submitted,  
HOWSON AND HOWSON  
Attorneys for Applicant  
BY Cathy A. Kodroff  
Cathy A. Kodroff  
Reg. No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Phone: (215) 540-9200  
Fax: (215) 540-5818



PTO/SB/08B (08-00)

Approved for use through 4/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Collection of Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

A check mark here if English language translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
				Application Number	10/617,038
				Filing Date	July 11, 2003
				First Named Inventor	Andersen et al
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	SSI5AUSA

#### OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column/row number(s), publisher, city and/or country where published	T <sup>2</sup>
	T	<b>MERRIFIELD</b> , Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide, <i>J. Am. Chem. Soc.</i> , 85:2149, (July 20, 1963)	
	U	<b>PEARSON ET AL</b> , Improved Tools for Biological Sequence Comparison, <i>Proc. Natl. Acad. Sci.</i> , Vol. 85, pp. 2444-2448, (April 1988)	
	V	<b>ROLPH ET AL</b> , Recombinant Viruses as Vaccines and Immunological Tools, <i>Curr. Opin. Immunol.</i> 9:517-24, (1997)	
	W	<b>ULMER ET AL</b> , Polynucleotide Vaccines, <i>Curr. Opin. Invest. Drugs</i> , 2(9):983-989 (1993)	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Washington, DC 20231.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.